Secondary osteoporosis associated with cancer therapy: a standard diagnostic and therapeutic procedure concerning patients with cancer treatment induced bone loss
Authors:
Špániková Beata 1,2; Payer Juraj 1,3; Jackuliak Peter 1,3; Mego Michal 4
Authors place of work:
Spoločnosť pre osteoporózu a metabolické ochorenia kostí
1; Interná-osteologická ambulancia, Onkologický ústav sv. Alžbety, s. r. o., Bratislava
2; V. interná klinika, LF UK a UNB, Nemocnica Ružinov, Bratislava
3; II. onkologická klinika, LF UK a Národný onkologický ústav, Bratislava
4
Published in the journal:
Clinical Osteology 2018; 23(1): 28-31
Category:
Summary
The Ministry of Health in cooperation with specialists has been actively engaged in the creation of standard preventive, diagnostic and therapeutic procedures. The standard diagnostic and therapeutic procedures provide a rough guide to the treatment for a diagnosis in question. The Society for Osteoporosis and Metabolic Bone Diseases has prepared a standard diagnostic and therapeutic procedure concerning patients with postmenopausal osteoporosis.
Key words:
androgen-deprivation therapy – bisphosphonates – denosumab – hormonal manipulation – aromatase inhibitors – osteoporosis – cancer treatment – zolendronate
Received 6. 8. 2018
Zdroje
- Body JJ, Bergmann P, Boonen S et al. Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporosis Int 2012; 23(Suppl 1): S1-S23.
- Early Breast Cancer Trialists Collaborative Group (EBCTCG). Adjuvant bisfosofnate treatement in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015; 386(10001): 1353–1361.
- Gnant M, Pfeiler G, Dubsky PC et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015; 386(9992): 433–443.
- Hadji P, Aapro MS, Body JJ et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 2017; 7:1–12. Dostupné z DOI: <http://doi: 10.1016/j.jbo.2017.03.001>.
- Hadji P, Coleman RE,Wilson C et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol 2016; 27(3): 379–390.
- Lipton A, Smith MR, Ellis GK et al. Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol 2012; 6: 287–303. Dostupné z DOI: <http://doi: 10.4137/CMO.S8511>.
- Morin JP, Domenech AC, Santos JP. Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy. Rheumatol Int 2014; 34(10): 1419–1425.
- Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19(14): 3306–3311.
- Smith MR, Egerdie B, Toriz NH et al. Denosumab in men Receving androgen-deprivation therapy for prostate cancer. New England Journal of Medicine 2009; 36(8): 745–755.
Štítky
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology OsteologyČlánok vyšiel v časopise
Clinical Osteology
2018 Číslo 1
- Memantine Eases Daily Life for Patients and Caregivers
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Metamizole vs. Tramadol in Postoperative Analgesia
- Memantine in Dementia Therapy – Current Findings and Possible Future Applications
Najčítanejšie v tomto čísle
- Postmenopausal osteoporosis: standard diagnostic and therapeutic practice
- Hypophosphatemic rickets linked to the X (XLH) chromosome – KRN 23 (burosumab) therapy: expert opinion of the Society for Metabolic Bone Diseases within the Czech Medical Association of J.E. Purkyně
- Long-term denosumab therapy for osteoporosis and its interruption: expert opinion of the Society for Metabolic Bone Diseases working group within the Czech Medical Association of J.E. Purkyně
- Secondary osteoporosis in patients with malignancies